Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Article CommentaryCommentary

Commentary from the Editors of the Continuing Education Section

Heiko Schöder and H. William Strauss
Journal of Nuclear Medicine August 2018, 59 (8) 1183;
Heiko Schöder
Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H. William Strauss
Memorial Sloan Kettering Cancer Center, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

See the associated articles on pages 1184, 1187, and 1195.

In the current issue of The Journal of Nuclear Medicine, we are presenting 3 articles discussing the treatment of differentiated thyroid cancer. Perhaps unusual for a journal section dedicated to education, this series of articles is not meant to provide definitive answers. Rather, we chose a different format for this edition. Education can be provided through systematic explanation and instruction, through examples, or through discussion and debate that forces us to take a fresh look at established practices. This time, we selected the latter, and we deliberately asked 2 groups of authors (Schmidt et al. on the one side (1) and Tuttle on the other (2)) to advocate different approaches that are currently used in clinical practice—one approach more traditional and perhaps conservative (Schmidt et al. (1)) and another approach based on risk stratification and individualized therapy (Tuttle (2)). We chose the positions discussed (extent of surgical resection, when and how to treat with radioiodine) on the basis of frequent discussions in thyroid tumor board meetings. We then asked a “knowledgeable outsider” who is unrelated to either group of authors to offer a balanced perspective (Pryma (3)). Our goal with this series of articles is to point out different paradigms in the clinical management of patients with thyroid cancer and to encourage discussion of these controversial topics within the nuclear medicine community and between nuclear medicine practitioners and other physicians (e.g., surgeons, endocrinologists, and medical oncologists) involved in the care of thyroid cancer patients.

The field of nuclear medicine is constantly in flux. Some imaging studies and radionuclide therapies described extensively in textbooks published 10 or 20 years ago are not even offered any longer. Revisiting, and questioning, traditional approaches are healthy for our profession and practice—as long as these discussions are based on data and facts. We need to acknowledge where data are sparse or inconclusive and strive for answers by conducting the necessary research.

When the American Thyroid Association started publishing its recent guidelines on the management of differentiated thyroid cancer (4,5), many in the nuclear medicine community were taken by surprise and questioned whether some of these recommendations were based on sufficient data. Regardless of one’s viewpoint, these guidelines prompted a discussion that was probably overdue on the management of thyroid cancer in the 21st century. Without doubt, there has been more progress in the management of thyroid cancer over the past decade than in the 3 or 4 decades before (6–9). Ultimately, we need to see if and how modern imaging and therapeutic approaches are going to improve the outcome of patients with thyroid cancer, both qualitatively and quantitively. In the meantime, we hope that you will enjoy these current articles; let us know what you think.

  • © 2018 by the Society of Nuclear Medicine and Molecular Imaging.

REFERENCES

  1. 1.↵
    1. Schmidt M,
    2. Görges R,
    3. Drzezga A,
    4. Dietlein M
    . A matter of controversy: is radioiodine therapy favorable in differentiated thyroid carcinoma? J Nucl Med. 2018;59:1195–1201.
    OpenUrl
  2. 2.↵
    1. Tuttle RM
    . Controversial issues in thyroid cancer management. J Nucl Med. 2018;59:1187–1194.
    OpenUrl
  3. 3.↵
    1. Pryma DA
    . Controversies on the use of radioiodine in thyroid cancer: we need more and better data. J Nucl Med. 2018;59:1184–1186.
    OpenUrl
  4. 4.↵
    1. Cooper DS,
    2. Doherty GM,
    3. Haugen BR,
    4. et al
    .; American Thyroid Association Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167–1214.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Haugen BR,
    2. Alexander EK,
    3. Bible KC,
    4. et al
    . 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Cabanillas ME,
    2. McFadden DG,
    3. Durante C
    . Thyroid cancer. Lancet. 2016;388:2783–2795.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Fagin JA,
    2. Wells SA Jr.
    . Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375:1054–1067.
    OpenUrl
  8. 8.
    1. Schlumberger M,
    2. Leboulleux S,
    3. Catargi B,
    4. et al
    . Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. Lancet Diabetes Endocrinol. May 25, 2018 [Epub ahead of print].
  9. 9.↵
    1. Schlumberger M,
    2. Tahara M,
    3. Wirth LJ,
    4. et al
    . Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372:621–630.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (8)
Journal of Nuclear Medicine
Vol. 59, Issue 8
August 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Commentary from the Editors of the Continuing Education Section
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Commentary from the Editors of the Continuing Education Section
Heiko Schöder, H. William Strauss
Journal of Nuclear Medicine Aug 2018, 59 (8) 1183;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Commentary from the Editors of the Continuing Education Section
Heiko Schöder, H. William Strauss
Journal of Nuclear Medicine Aug 2018, 59 (8) 1183;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Info & Metrics
  • PDF

Related Articles

  • Controversies on the Use of Radioiodine in Thyroid Cancer: We Need More and Better Data
  • Controversial Issues in Thyroid Cancer Management
  • A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma?
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • NRC Rejects Petitions to End Reliance on LNT Model
  • Prescribed Activity of 131I Therapy in Differentiated Thyroid Cancer
Show more Commentary

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire